Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIN1001 in Idiopathic Pulmonary Fibrosis
NCT04643769Phase 1Suspended
- Sponsor
- Orinove Inc.
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ORIN1001 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Orinove Inc. Primary endpoints: Blood pressure up to 60 days, Heart Rate up to 60 days and 14 more. Started Feb 2021; status: suspended.
02
Drugs
ORIN1001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04643769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643769.